BioXcel Therapeutics Files Q1 2025 10-Q
Ticker: BTAI · Form: 10-Q · Filed: May 12, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
BTAI Q1 2025 10-Q filed. Check financials.
AI Summary
BioXcel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the report.
Why It Matters
This filing provides investors with the latest financial performance and operational status of BioXcel Therapeutics, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a biotechnology company, BioXcel Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 3102000 — Total Assets (As of March 31, 2025)
- 5468000 — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- 20250512 (date) — Filing date
- 0001720893 (company) — Central Index Key for BioXcel Therapeutics
- 203-643-8060 (phone_number) — Business phone number
FAQ
What were BioXcel Therapeutics' total assets as of March 31, 2025?
BioXcel Therapeutics' total assets were $3,102,000 as of March 31, 2025.
What were BioXcel Therapeutics' total liabilities as of March 31, 2025?
BioXcel Therapeutics' total liabilities were $5,468,000 as of March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 12, 2025.
What is the fiscal year end for BioXcel Therapeutics?
The fiscal year end for BioXcel Therapeutics is December 31.
What is the SEC file number for BioXcel Therapeutics?
The SEC file number for BioXcel Therapeutics is 001-38410.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).